A Multiple-dose Study of LY3031207 in Healthy Participants

• Pharmacokinetics: Maximum concentration (Cmax) of LY3031207 [ Time Frame: Predose up to 48 hours post last dose ] [ Designated as safety issue: No ]
• Pharmacokinetics: Area under the concentration curve (AUC) of LY3031207 [ Time Frame: Predose up to 48 hours post last dose ] [ Designated as safety issue: No ]
• Pharmacokinetics: Time of maximum concentration (Tmax) of LY3031207 [ Time Frame: Predose up to 48 hours post last dose ] [ Designated as safety issue: No ]
• Pharmacokinetics: Maximum concentration (Cmax) of simvastatin [ Time Frame: Predose up to 48 hours post last dose ] [ Designated as safety issue: No ]
• Pharmacokinetics: Area under the concentration curve (AUC) of simvastatin [ Time Frame: Predose up to 48 hours post last dose ] [ Designated as safety issue: No ]
• Pharmacokinetics: Time of maximum concentration (Tmax) of simvastatin [ Time Frame: Predose up to 48 hours post last dose ] [ Designated as safety issue: No ]
• Percent change from baseline of urinary prostacyclin I (PGI) metabolite excretion [ Time Frame: Predose up to 12 hours prior to last dose ] [ Designated as safety issue: No ]
• Percent change from baseline of urinary prostaglandin E (PGE) metabolite excretion [ Time Frame: Predose up to time of last dose ] [ Designated as safety issue: No ]
• Percent change from baseline of urinary thromboxane A (TXA) metabolite excretion [ Time Frame: Predose up to 12 hours prior to last dose ] [ Designated as safety issue: No ]

The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it when given to healthy Japanese and non-Japanese participants as multiple doses. In addition, effects of 28-day oral dosing of LY3131207 on the amount of a cholesterol-lowering drug (simvastatin) that gets into the blood stream and how long the body takes to get rid of it will be determined. The effects of LY3131207 after single and 28-day dosing on blood pressure will also be studied. Information about any side effects that may occur will be collected.

• Drug: Placebo
  Capsules administered orally
• Drug: LY3031207
  Administered orally
• Drug: Celecoxib
  Administered orally
• Drug: Simvastatin
  Administered orally

• Placebo Comparator: Placebo
  Daily oral administration of placebo for 28 days. Dose will match corresponding LY3031207 dosage.
  Intervention: Drug: Placebo
• Experimental: LY3031207
  Daily oral administration of 25 milligrams up to 450 milligrams of LY3031207 for 28 days.
  Intervention: Drug: LY3031207
• Active Comparator: Celecoxib
  Daily oral administration of 400 milligrams celecoxib for 28 days. Positive control for LY3031207.
  Intervention: Drug: Celecoxib
• LY3031207 + Simvastatin
  Daily oral administration of 75 milligram or 225 milligram of LY3031207 for 28 days. Single oral 10 milligram dose of simvastatin administered open label before and after 28-day dosing of LY3031207.
  Intervention: Drug: Simvastatin

Inclusion Criteria:

• Overtly healthy individuals based on the history and physical examinations as determined by the investigator, including first generation Japanese
• Body mass index between 17.0 and 32.0 kilograms per square meter (kg/m^2), inclusive

Exclusion Criteria:

• Have known allergies to LY3031207 or any components of the formulation, simvastatin or related compounds (other 3-Hydroxy-3-Methyl-Glutaryl-CoA [HMG CoA] reductase inhibitors), celecoxib, or sulfonamides. Participants with known aspirin allergy or allergic reaction to nonsteroidal anti-inflammatory drugs (NSAIDs) should also be excluded